SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is driving the discussion, with traders citing reported losses, concerns about further share dilution and questions about Truth Socials engagement as reasons for skepticism. Political backlash and midterm worries add to the bearish tone, while some holders still view the decline as a buying opportunity.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs continued slide to fresh lows is drawing attention, with traders citing analyst target cuts and concerns about weak housing and roofing demand, high rates, and the debt and dilution tied to its acquisition-led expansion. The conversation is sharply divided between frustrated holders calling for clearer communication and evidence of integration progress, and bullish investors treating the selloff as an opportunity to accumulate ahead of earnings.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp advance is being attributed mainly to Morgan Stanley naming it a top pick, citing expected AWS growth and AI opportunities. Traders are broadly bullish on the rebound, though some question whether the upgrade-driven move will hold ahead of earnings.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff has focused attention on its debt burden, rising financing costs and whether AI demand can translate into cash flow; traders are divided over whether these risks threaten the business or are being overstated. Goldman Sachs Buy upgrade after the decline prompted hopes for a rebound, but skepticism about the upgrade and fading gains remained prominent.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and underperformance relative to Bitcoin dominate discussion, with traders blaming weak management and the lack of signed AI/data-center tenant deals as the company pursues a pivot beyond mining. Bearish frustration over the falling shares and perceived short pressure competes with dip-buying and hopes that a lease announcement or Bitcoin strength could improve sentiment.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met both co-primary and all secondary endpoints in the Phase 3 APOLLO trial for EPP, strengthening the case for an NDA resubmission after the FDAs earlier rejection. Traders are broadly bullish on the data and speculate about a short squeeze, while others point to profit-taking, resistance, and concerns about dizziness or a possible sell-the-news reaction.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention after traders cited strong earnings and year-over-year revenue growth, alongside optimism that AI data-center demand for indium-phosphide substrates can support further growth. The reaction is sharply divided: bulls focus on the AI-optics opportunity, while bears point to the stocks steep run-up, rich valuation, China-related risks, and volatile pullbacks.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular shares are under pressure as EyePoints failed wet-AMD trial has raised concerns among traders about the TKI approach, while the departure of Oculars chief strategy officer and uncertainty around the AXPAXLI NDA add to unease. Some traders see the setback as a warning about shared clinical risks; others argue AXPAXLIs positive SOL-1 results and FDA-aligned filing path set it apart.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is drawing attention amid a sharp, persistent selloff, with traders citing solar-sector weakness, financing-rate sensitivity, and fears about the companys debt and possible bankruptcy. Bulls counter with Sunruns virtual power plant and AI-power potential and speculate about policy support, but those themes have not eased widespread frustration over the stocks decline.

Annaly Capital Management, Inc. engages in the investment and financing of residential and commercial assets. It operates through the following segments: Agency, Residential Credit, Mortgage Servicing Rights (MSR), and Corporate and Other. The Agency segment invests in agency mortgage-backed securities. The Residential Credit segment is involved in non-agency residential mortgage assets within securitized products and whole loan markets. The MSR segment provides the right to service residential mortgage loans in exchange for a portion of the interest payments made on the loans. The company was founded by Michael A. J. Farrell and Wellington Jamie Denahan-Norris on November 25, 1996 and is headquartered in New York, NY.

Annaly Capital Management Inc

Annaly is drawing attention as mortgage REITs sell off and shares hit a reported 52-week low; traders point to rate concerns and mortgage-bond repricing. Some holders are buying the dip for the high dividend, while others worry about book value, leverage and further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SLS Stock Climbs Pre-Market: CEO's Early Anniversary Post Has Retail Bulls Buzzing About Major News

Equity

Stergiou said SELLAS was entering its “next chapter” with GPS and SLS009 but did not disclose a clinical trial timeline or confirm an upcoming announcement.


Biotech ETF (BBC) Touches a New 52-Week High

The BBC ETF hit a 52-week high as strong trial updates and biotech momentum raise hopes for more gains ahead.

Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?

Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.

Biotech ETF (BBC) Touches Fresh 52-Week High

Biotech ETF BBC hits a 52-week high, likely fueled by strong clinical trial results and rising M&A activity, and renewed risk-on sentiment.

Why Did NGNE Stock Surge 25% In Pre-Market Today?

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

Why Did UPB Stock Plunge 40% Today?

The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?

The European Patent Office revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.

GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount

The offering includes 11.125 million shares of common stock priced at $24.00 per share, a 5.1% discount to Thursday’s close at $25.31.

Why Did GLUE Stock Surge Over 50% In Premarket Today?

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.

Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?

Q4's top ETF winners -- silver, biotech and lithium -- outpaced markets. Can SIVR, SLV, BBC and LITP extend gains into 2026?

ETFis Series Trust I - Virtus Biotech Clinical Trials ETF

Bullish Sentiment

<ul class="summary-bullets"><li>In a LinkedIn post, SELLAS Life Sciences CEO Angelos Stergiou marked the company’s 15th anniversary by reflecting on its evolution.</li><li>The CEO highlighted the company’s progress in advancing late-stage oncology programs.</li><li>The post did not provide a timeline for clinical updates, but its references to SELLAS’ “next chapter” prompted speculation among retail investors about a possible upcoming catalyst.</li></ul>SELLAS Life Sciences (SLS) shares rose in early morning trade on Monday after an anniversary post from CEO Angelos Stergiou on LinkedIn sparked speculation among retail investors that major news may be on the horizon.&nbsp;In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/posts/dr-angelos-m-stergiou-md-scd-hc-14140b8_fifteen-years-ago-this-week-sellas-life-share-7517893213051990016--G3U/">post</a> on LinkedIn, Stergiou marked SELLAS’ 15th anniversary and said the company is stepping into its “next chapter” with its two lead programs, GPS and SLS009. The post thanked shareholders, partners, employees and trial participants. It did not mention trial timing.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> gained as much as 1.5% in pre-market trade and was among the top trending tickers on Stocktwits at the time of writing.&nbsp;<h2 class="st-heading-2">Why SELLAS Investors Are Reading Into The CEO’s Post</h2>On Stocktwits, retail sentiment around SLS stock trended in ‘bullish’ territory over the past day, accompanied by chatter at ‘high’ levels. Platform data showed a 90% increase in message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_10_19_082540_30139bbdb2.png" alt="Screenshot 2026-10-19 082540.png" width="1264" height="688"><figcaption>SLS stock retail sentiment on October 19 as of 8:00 a.m. ET | Source: Stocktwits</figcaption></figure>Some retail investors questioned whether the timing and wording of the anniversary message pointed to an upcoming catalyst.&nbsp;<stembedurl>https://stocktwits.com/sarahrah/message/666816915</stembedurl>Another investor pointed to Stergiou’s relative silence over the preceding three months and speculated that the “transition language” could signal a major corporate development.&nbsp;<stembedurl>https://stocktwits.com/Issidur/message/666816256</stembedurl>Others were less convinced. “This is nothing more than a victory lap,” one user&nbsp;<a href="https://stocktwits.com/Petey3163/message/666817123">wrote</a>. Another bullish investor also&nbsp;<a href="https://stocktwits.com/BioTechBling/message/666816222">viewed</a> the post as a victory lap but said they expected trial news to follow.<h2 class="st-heading-2">REGAL Trial Remains The Main Catalyst</h2>Investors are primarily watching the final analysis of GPS (galinpepimut-S), an immunotherapy that targets the WT1 protein found in many tumor types. SELLAS licenses the treatment from Memorial Sloan Kettering Cancer Center and is evaluating it in the Phase 3 REGAL trial in patients with acute myeloid leukemia (AML) who achieved complete remission after second-line salvage therapy. The trial’s primary endpoint is overall survival.REGAL passed its interim futility, efficacy and safety review at 60 deaths in early 2025. The final analysis is triggered at 80 deaths. SELLAS reported 72 deaths as of December 26 last year and 78 as of May 11, 2026.A German report in August claimed the threshold had been reached, but SELLAS has not confirmed that report. Investors are&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-retail-bulls-ash-embargo-keeping-regal-results-under-wraps/cZx8BVNRBtC">now watching</a> for announcements at the American Society of Hematology's (ASH) annual meeting in New Orleans for clues on Sellas’ next clinical update.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-roadster-nvidia-space-ai-push-nadella-security-warning-mag-7-ceos-this-week/cZxjushRBtE">Elon Musk’s Roadster, Nvidia’s Space AI Push, Nadella’s Security Warning: Mag 7 Voices This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the SELLAS Life Sciences Group logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Stergiou said SELLAS was entering its “next chapter” with GPS and SLS009 but did not disclose a clinical trial timeline or confirm an upcoming announcement.

SLS Stock Gains Pre-Market: CEO’s ‘Next Chapter’ Message Has Retail Traders Looking For A Catalyst

ETFis Series Trust I - Virtus LifeSci Biotech Clinical Trials ETF

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Feed

News

Sentiment

Fundamentals

Info

BBC News